FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1969056907> ?p ?o ?g. }

• W1969056907 endingPage "1461" @default.
• W1969056907 startingPage "1455" @default.
• W1969056907 abstract "High-dose melphalan 140 mg/m2 is the standard of care for patients with multiple myeloma (MM) with renal insufficiency (RI). Palifermin as a cytoprotective agent has demonstrated efficacy in reducing the intensity and duration of oral mucositis (OM) in patients who receive intensive chemotherapy/radiotherapy. There is no prospective data on the use of palifermin in patients with MM with RI. Eligibility criteria: creatinine clearance ≤60 mL/minute/1.73 m2, age >18 years, no dialysis, no active OM, and a suitable candidate for autologous stem cell transplant (ASCT). Melphalan dose ranged from 140 to 200 mg/m2 and escalated at the increment of 20 mg/m2. Six dosages of palifermin 60 mcg/kg/day were given intravenously between day –5 to day +3. Dose escalations were to stop if dose-limiting toxicities (DLTs) occurred at melphalan dose in ≥2 of 3 patients, with that dose declared as the maximal administered dose and the level below where ≤1 of 6 patients had DLTs was considered the maximally tolerated dose (MTD). Nineteen patients were enrolled from June 2007 to June 2011. Data on 15 evaluable patients is reported as 4 patients were removed. Median age was 59 years (range, 36-67 years). The overall incidence of OM ≥ grade 3 was 53% (8 of 15) and a median duration of ≥grade 3 OM was 6.5 days (range, 3-42 days). One patient in L2 (melphalan 160 mg/m2) developed atrial fibrillation on day +9. Two patients in L4 (melphalan 200 mg/m2) developed grade 4 OM, hence reaching DLT. No DLT was observed in 6 patients enrolled in L3 (melphalan 180 mg/m2). Palifermin has permitted safe dose escalation of melphalan up to 180 mg/m2 in patients with RI. High-dose melphalan 140 mg/m2 is the standard of care for patients with multiple myeloma (MM) with renal insufficiency (RI). Palifermin as a cytoprotective agent has demonstrated efficacy in reducing the intensity and duration of oral mucositis (OM) in patients who receive intensive chemotherapy/radiotherapy. There is no prospective data on the use of palifermin in patients with MM with RI. Eligibility criteria: creatinine clearance ≤60 mL/minute/1.73 m2, age >18 years, no dialysis, no active OM, and a suitable candidate for autologous stem cell transplant (ASCT). Melphalan dose ranged from 140 to 200 mg/m2 and escalated at the increment of 20 mg/m2. Six dosages of palifermin 60 mcg/kg/day were given intravenously between day –5 to day +3. Dose escalations were to stop if dose-limiting toxicities (DLTs) occurred at melphalan dose in ≥2 of 3 patients, with that dose declared as the maximal administered dose and the level below where ≤1 of 6 patients had DLTs was considered the maximally tolerated dose (MTD). Nineteen patients were enrolled from June 2007 to June 2011. Data on 15 evaluable patients is reported as 4 patients were removed. Median age was 59 years (range, 36-67 years). The overall incidence of OM ≥ grade 3 was 53% (8 of 15) and a median duration of ≥grade 3 OM was 6.5 days (range, 3-42 days). One patient in L2 (melphalan 160 mg/m2) developed atrial fibrillation on day +9. Two patients in L4 (melphalan 200 mg/m2) developed grade 4 OM, hence reaching DLT. No DLT was observed in 6 patients enrolled in L3 (melphalan 180 mg/m2). Palifermin has permitted safe dose escalation of melphalan up to 180 mg/m2 in patients with RI." @default.
• W1969056907 created "2016-06-24" @default.
• W1969056907 creator A5005086749 @default.
• W1969056907 creator A5016774003 @default.
• W1969056907 creator A5028497782 @default.
• W1969056907 creator A5034791164 @default.
• W1969056907 creator A5037082058 @default.
• W1969056907 creator A5042677328 @default.
• W1969056907 creator A5046786751 @default.
• W1969056907 creator A5051092535 @default.
• W1969056907 creator A5055027283 @default.
• W1969056907 creator A5076385097 @default.
• W1969056907 creator A5086538924 @default.
• W1969056907 creator A5091089490 @default.
• W1969056907 date "2012-09-01" @default.
• W1969056907 modified "2023-10-03" @default.
• W1969056907 title "Melphalan 180 mg/m2 Can Be Safely Administered As Conditioning Regimen before an Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma Patients with Creatinine Clearance 60 mL/min/1.73 m2 or Lower with Use of Palifermin for Cytoprotection: Results of a Phase I Trial" @default.
• W1969056907 cites W1605669489 @default.
• W1969056907 cites W1788256932 @default.
• W1969056907 cites W1931964440 @default.
• W1969056907 cites W1977710099 @default.
• W1969056907 cites W1985234560 @default.
• W1969056907 cites W1985482871 @default.
• W1969056907 cites W1991216736 @default.
• W1969056907 cites W2002829541 @default.
• W1969056907 cites W2003111859 @default.
• W1969056907 cites W2010717111 @default.
• W1969056907 cites W2039718569 @default.
• W1969056907 cites W2060938599 @default.
• W1969056907 cites W2073292917 @default.
• W1969056907 cites W2082134267 @default.
• W1969056907 cites W2089107230 @default.
• W1969056907 cites W2097067451 @default.
• W1969056907 cites W2102591890 @default.
• W1969056907 cites W2107057207 @default.
• W1969056907 cites W2118063672 @default.
• W1969056907 cites W2120370912 @default.
• W1969056907 cites W2120929463 @default.
• W1969056907 cites W2124602753 @default.
• W1969056907 cites W2127143739 @default.
• W1969056907 cites W2135455274 @default.
• W1969056907 cites W2160115655 @default.
• W1969056907 cites W2161109822 @default.
• W1969056907 cites W2316987662 @default.
• W1969056907 cites W3145716452 @default.
• W1969056907 cites W4317527937 @default.
• W1969056907 doi "https://doi.org/10.1016/j.bbmt.2012.03.010" @default.
• W1969056907 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3782285" @default.
• W1969056907 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22453252" @default.
• W1969056907 hasPublicationYear "2012" @default.
• W1969056907 type Work @default.
• W1969056907 sameAs 1969056907 @default.
• W1969056907 citedByCount "12" @default.
• W1969056907 countsByYear W19690569072013 @default.
• W1969056907 countsByYear W19690569072014 @default.
• W1969056907 countsByYear W19690569072015 @default.
• W1969056907 countsByYear W19690569072016 @default.
• W1969056907 countsByYear W19690569072018 @default.
• W1969056907 countsByYear W19690569072020 @default.
• W1969056907 countsByYear W19690569072023 @default.
• W1969056907 crossrefType "journal-article" @default.
• W1969056907 hasAuthorship W1969056907A5005086749 @default.
• W1969056907 hasAuthorship W1969056907A5016774003 @default.
• W1969056907 hasAuthorship W1969056907A5028497782 @default.
• W1969056907 hasAuthorship W1969056907A5034791164 @default.
• W1969056907 hasAuthorship W1969056907A5037082058 @default.
• W1969056907 hasAuthorship W1969056907A5042677328 @default.
• W1969056907 hasAuthorship W1969056907A5046786751 @default.
• W1969056907 hasAuthorship W1969056907A5051092535 @default.
• W1969056907 hasAuthorship W1969056907A5055027283 @default.
• W1969056907 hasAuthorship W1969056907A5076385097 @default.
• W1969056907 hasAuthorship W1969056907A5086538924 @default.
• W1969056907 hasAuthorship W1969056907A5091089490 @default.
• W1969056907 hasBestOaLocation W19690569071 @default.
• W1969056907 hasConcept C126322002 @default.
• W1969056907 hasConcept C126894567 @default.
• W1969056907 hasConcept C141071460 @default.
• W1969056907 hasConcept C2776364478 @default.
• W1969056907 hasConcept C2776694085 @default.
• W1969056907 hasConcept C2778496288 @default.
• W1969056907 hasConcept C2778684742 @default.
• W1969056907 hasConcept C2779050716 @default.
• W1969056907 hasConcept C2779978075 @default.
• W1969056907 hasConcept C2780306776 @default.
• W1969056907 hasConcept C2781413609 @default.
• W1969056907 hasConcept C2911091166 @default.
• W1969056907 hasConcept C71924100 @default.
• W1969056907 hasConceptScore W1969056907C126322002 @default.
• W1969056907 hasConceptScore W1969056907C126894567 @default.
• W1969056907 hasConceptScore W1969056907C141071460 @default.
• W1969056907 hasConceptScore W1969056907C2776364478 @default.
• W1969056907 hasConceptScore W1969056907C2776694085 @default.
• W1969056907 hasConceptScore W1969056907C2778496288 @default.
• W1969056907 hasConceptScore W1969056907C2778684742 @default.
• W1969056907 hasConceptScore W1969056907C2779050716 @default.
• W1969056907 hasConceptScore W1969056907C2779978075 @default.
• W1969056907 hasConceptScore W1969056907C2780306776 @default.
• W1969056907 hasConceptScore W1969056907C2781413609 @default.

• next